Clinical Advances in Diagnostics and Therapies for FGFR-Altered Cancer: February 2021 Updates: Part Two

Clinical Advances in Diagnostics and Therapies for FGFR-Altered Cancer: February 2021 Updates: Part Two

Online Course | Specialties: Family Medicine, Internal Medicine, Oncology
Released: 3/31/2021
Expires: 3/30/2022
Max Credits: 1.75
Jump to Education

Sameek Roychowdhury, MD, PhD 
Associate Professor, Department of Internal Medicine 
Division of Medical Oncology 
Medical Director, CLIA Certified Cancer Genomics Laboratory 
The Ohio State University, James Cancer Hospital and Comprehensive Cancer Center
Columbus, OH

Michael K. Wendt, PhD 
Associate Professor 
Medicinal Chemistry and Molecular Pharmacology 
Director, Cancer Biology Training Program 
Purdue Center for Cancer Research 
West Lafayette, IN 
Milind Javle, MD 
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center 
Houston, TX

Activity Planners
Julie Blum, PhD
Director, Clinical Content
Baltimore, MD

Samantha Gordon, MS
Accreditation Manager 
Baltimore, MD

Amy Sison
Director of CME
Baltimore, MD

Kathryn Schaefer, MSN, RN, CPHRM
Associate Director, Education Quality and Compliance
East Lansing, MI 

Learning Objectives
Upon completion, participants should be able to:

  • Explain the rationale to therapeutically target the FGFR signaling pathway in cancer  
  • Review recent and ongoing clinical trials for FGFR inhibitors with regard to biomarkers, mechanisms of action, efficacy, side effects, and safety 

Target Audience
This activity is intended for oncology professionals including physicians, physician assistants, nurse practitioners, nurses, and researchers. 
Statement of Need
Advances with technology and an increased understanding of the molecular pathways that drive oncogenesis has led to the development of novel therapies targeting fibroblast growth factor receptor (FGFR) aberrations in multiple tumor types. Several of the FGFR inhibitors are producing profound and durable responses in cancer treatment. An FGFR inhibitor recently gained FDA approval in the treatment of urothelial cancer, and other approvals are anticipated. Optimizing the clinical use of FGFR inhibitors will depend on the appropriate selection of patients who are most likely to benefit from these agents as well as the selection of the optimal FGFR-targeting agent, taking into account the selectivity of the agents, efficacy and toxicity profiles, and the design and implementation of novel strategies to overcome resistance mechanisms and further improve response rates. To that end, developing a clear understanding of the emerging research and the evolving landscape of FGFR inhibitors in various tumor types is needed to effectively optimize the use these agents in clinical practice. 

Providership Statement
Provided by Med-IQ. 
Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Med-IQ designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Med-IQ is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This nursing activity has been approved for up to 1.75 contact hours.

Physician assistants and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available. 

Medium/Method of Participation
To receive credit, read the introductory CME/CE material, watch the webcast, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
Initial Release Date: March 31, 2021
Expiration Date: March 30, 2022
Estimated Time to Complete This Activity: 1 hour and 45 minutes

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Off-label/unapproved drug uses or products are mentioned within this activity. 

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation. 

Milind Javle, MD
Consulting fees/advisory boards: AstraZeneca, Bristol-Myers Squibb, Basilea Pharmceutica Ltd., EMD Serono, Inc., Incyte Corporation, Merck & Co, Inc., OncoSil Medical, QED Therapeutics, Taiho Pharmaceutical Group 
Fees received for promotional/non-CME activities: Incyte Corporation 

Sameek Roychowdhury, MD, PhD 
Consulting fees/advisory boards: Incyte Corporation, Merck & Co., Inc.  

Michael K. Wendt, PhDhas indicated no real or apparent conflicts.  

The peer reviewers and activity planners have no financial relationships to disclose. 
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis. 
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity. 
Contact Information        
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email

System Requirements



  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy notice, please visit:

This activity is available free of charge to participants.

Acknowledgement of Commercial Support
This activity is supported by an educational grant from QED Therapeutics.

© 2021 Copyrighted

Here are the key takeaways from this activity. Deeper insights and evidence, plus an opportunity to receive credit, are available at the "Continue" button below.

  • In addition to genetic alterations, FGFR signaling can be enhanced through epithelial-mesenchymal transition
  • Depletion of FGFR1 in tumor cells causes increased T-cell infiltration; FGFR inhibitors have the potential to diminish immune cell function; in pre-clinical models, erdafitinib has been shown to inhibit the proliferation of tumor-infiltrated T-cells
  • The phase 3 ABC-06 trial showed that the endpoint for overall survival was met; adjusted HR was 0.69 (95% CI, 0.50-0.97; P = .031) in favor of the ASC + mFOLFOX arm
  • The use of FGFR inhibitors in FGFR fusion–positive cholangiocarcinoma leads to the following objective response rates:
    • o 23% with infigratinib
    • o 35.5% with pemigatinib
    • o 34% with futibatinib
    • o 20.7% with derazantinib
    • o 57.1% with erdafitinib
View reference list.

By clicking "Continue," you confirm that you have reviewed the CME information.


Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

COPYRIGHTED. Republication or redistribution of Med‑IQ content, including by framing, is prohibited without prior written consent. Med‑IQ shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.